These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 17387390

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
    Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH.
    J Clin Oncol; 2001 Feb 01; 19(3):697-704. PubMed ID: 11157020
    [Abstract] [Full Text] [Related]

  • 5. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS.
    Clin Lymphoma; 2002 Dec 01; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Laadem A, Seiter K.
    J Clin Oncol; 2010 Sep 20; 28(27):4207-13. PubMed ID: 20713865
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
    Shin HY, Kang HJ, Park ES, Choi HS, Ahn HS, Kim SY, Chung NG, Kim HK, Kim SY, Kook H, Hwang TJ, Lee KC, Lee SM, Lee KS, Yoo KH, Koo HH, Lee MJ, Seo JJ, Moon HN, Ghim T, Lyu CJ, Lee WS, Choi YM.
    Pediatr Blood Cancer; 2006 Apr 20; 46(4):439-45. PubMed ID: 16123985
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
    Vachhani P, Baron J, Freyer CW, Miller A, Wetzler M, Thompson JE, Griffiths EA, Wang ES.
    Leuk Res; 2021 Aug 20; 107():106588. PubMed ID: 33957371
    [Abstract] [Full Text] [Related]

  • 13. Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
    Zaidi SZ, Aljurf M.
    J Clin Oncol; 2004 Aug 15; 22(16):3430-1; author reply 3431-2. PubMed ID: 15310789
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
    Galardy PJ, Hochberg J, Perkins SL, Harrison L, Goldman S, Cairo MS.
    Br J Haematol; 2013 Nov 15; 163(3):365-72. PubMed ID: 24032600
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy.
    Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M.
    Pharmacotherapy; 2006 Feb 15; 26(2):242-7. PubMed ID: 16466328
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.